David Kirn, M.D.
Equibles does not estimate personal net worth.
Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FDMT alertsAbout David Kirn, M.D.
David Kirn, M.D. is recorded as CEO at 4D Molecular Therapeutics, Inc. (FDMT) since January 1, 2026. 4D Molecular Therapeutics, Inc. reported in an 8-K filed January 7, 2026 that David Kirn, M.D. was appointed President and Chief Executive Officer, effective January 1, 2026. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at 4D Molecular Therapeutics, Inc. includes David Kirn (CEO and Board Member), Ashoo Gupta (CFO), Kristian Humer (CFO and Chief Accounting Officer) and 7 others.
“Effective January 1, 2026, following the resignation of Dr. Kamal as President, the Board of Directors of the Company (the "Board") appointed David Kirn, M.D., the Company's current Chief Executive Officer, as the President and Chief Executive Officer of the Company.”
Affiliation history
-
Current
2026-01-01–present
Company network
Leadership on record at 4D Molecular Therapeutics, Inc.
- David Kirn CEO, Board Member
- Ashoo Gupta CFO
- Kristian Humer CFO, Chief Accounting Officer
- Uneek Mehra CFO, Chief Accounting Officer
- Fred Kamal COO
- Charles Theuer Board Member
- Glenn Sblendorio Board Member
- Jacob Chacko Board Member
- John F. Milligan Board Member
- Nancy Miller-Rich Board Member